27-Hydroxycholesterol causes brain immune cells to age after iron buildup, which may be reduced by Deferoxamine

27-hydroxycholesterol was linked to microglial senescence, iron disruption, and brain-aging phenotypes that deferoxamine partly suppressed in experimental models.

This translational preclinical study combined an AD patient plasma correlation with mouse 27-OHC administration and BV-2 cell experiments measuring cognition, anxiety-like behavior, senescence markers, microglial polarization, iron-homeostasis proteins, ROS, and mitochondrial function.

The human evidence is correlational and the mechanistic treatment signal comes from mouse and cell models rather than clinical testing of deferoxamine for brain aging.